Susquehanna International Group
DNLI icon

Susquehanna International Group’s Denali Therapeutics DNLI Stock Holding History

Susquehanna International Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
10,900
-21,100
-66% -$420K ﹤0.01% 11610
2025
Q4 		$528K Sell
32,000
-44,900
-58% -$758K ﹤0.01% 8657
2025
Q3 		$1.12M Buy
+76,900
New +$1.1M ﹤0.01% 7077
2024
Q2 		– Sell
-69,800
Closed -$1.43M – 12246
2024
Q1 		$1.43M Buy
69,800
+57,500
+467% +$1.08M ﹤0.01% 6112
2023
Q4 		$264K Buy
+12,300
New +$244K ﹤0.01% 10095
2023
Q3 		– Sell
-12,900
Closed -$381K – 12182
2023
Q2 		$381K Sell
12,900
-14,300
-53% -$402K ﹤0.01% 8949
2023
Q1 		$627K Buy
+27,200
New +$749K ﹤0.01% 8015
2022
Q4 		– Sell
-7,600
Closed -$233K – 12668
2022
Q3 		$233K Sell
7,600
-2,900
-28% -$94.3K ﹤0.01% 10445
2022
Q2 		$309K Sell
10,500
-39,400
-79% -$1.03M ﹤0.01% 9490
2022
Q1 		$1.6M Sell
49,900
-64,600
-56% -$2.22M ﹤0.01% 5973
2021
Q4 		$5.11M Buy
114,500
+87,600
+326% +$4.15M ﹤0.01% 3700
2021
Q3 		$1.36M Buy
26,900
+5,000
+23% +$282K ﹤0.01% 6750
2021
Q2 		$1.72M Sell
21,900
-32,700
-60% -$2.02M ﹤0.01% 6279
2021
Q1 		$3.12M Buy
54,600
+38,100
+231% +$2.55M ﹤0.01% 4872
2020
Q4 		$1.38M Sell
16,500
-31,500
-66% -$1.9M ﹤0.01% 5927
2020
Q3 		$1.72M Buy
48,000
+34,700
+261% +$1.05M ﹤0.01% 4910
2020
Q2 		$322K Buy
13,300
+800
+6% +$18.8K ﹤0.01% 8232
2020
Q1 		$219K Sell
12,500
-22,500
-64% -$469K ﹤0.01% 8523
2019
Q4 		$610K Sell
35,000
-50,900
-59% -$847K ﹤0.01% 6541
2019
Q3 		$1.32M Buy
85,900
+70,100
+444% +$1.34M ﹤0.01% 5104
2019
Q2 		$328K Buy
+15,800
New +$354K ﹤0.01% 8124
2018
Q3 		– Sell
-12,500
Closed -$191K – 9397
2018
Q2 		$191K Buy
+12,500
New +$236K ﹤0.01% 8651

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's DNLI Position: Q1 2026 in Review

Susquehanna International Group increased its Denali Therapeutics (DNLI) stake by 45% in Q1 2026, buying an estimated $313K and bringing the position to 50,475 shares worth $969K. The position accounts for ﹤0.01% of the portfolio, ranked #7967.

Susquehanna International Group first reported a position in DNLI in Q2 2019 and has held it in 27 quarters since. The position peaked at $7.85M in Q1 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Susquehanna International Group held 50,475 shares of Denali Therapeutics worth $969K as of Q1 2026.
  • Susquehanna International Group bought 15,707 Denali Therapeutics shares in Q1 2026, an estimated $313K.
  • Denali Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7967 holding.
  • Susquehanna International Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Denali Therapeutics position peaked at $7.85M in Q1 2023.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.